Qulipta (atogepant) is FDA approved for both chronic and episodic migraine prevention in adults. Ongoing data shows safety and promising results in patients who've failed multiple other preventives.

A migraine attack is more than a headache. It can derail your entire day.

Analysts at GlobalData have said they expect Qulipta to get approval for chronic migraine prevention in 2023, helping it to sales of $1.2 billion by 2027, with growth coming particularly among ...

It’s a pill you take daily. Qulipta is approved for both the prevention of episodic migraine and chronic migraine. The same contraindications as the other small-molecule CGRP inhibitors apply ...

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine. Qulipta (atogepant ...